Home » Stocks » CVSI

CV Sciences, Inc. (CVSI)

Stock Price: $0.4300 USD -0.0100 (-2.27%)
Updated Jun 14, 2021 3:59 PM EDT - Market closed
Market Cap 43.23M
Revenue (ttm) 21.00M
Net Income (ttm) n/a
Shares Out 108.43M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE 15.63
Dividend n/a
Dividend Yield n/a
Trading Day June 14
Last Price $0.4300
Previous Close $0.4400
Change ($) -0.0100
Change (%) -2.27%
Day's Open 0.4435
Day's Range 0.4100 - 0.4440
Day's Volume 456,156
52-Week Range 0.3500 - 1.1200

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

1 month ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

1 month ago - GlobeNewsWire

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today an...

2 months ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -350.00% and -22.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) product...

2 months ago - GlobeNewsWire

CV Sciences (OTC:CVSI) will be releasing its next round of earnings this Thursday, March 18. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.

2 months ago - Benzinga

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

While cannabis legalization may not be a slam-dunk, that hasn't stopped investors from sending marijuana penny stocks to higher highs. The post 4 Marijuana Penny Stocks Winning Under Democratic Leadersh...

Other stocks mentioned: ALEAF, HRVSF, MRMD
5 months ago - InvestorPlace

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

6 months ago - GlobeNewsWire

CV Sciences Inc's (CVSI) CEO Joe Dowling on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Full line of soothing hemp extracts formulated exclusively for dogs and cats Full line of soothing hemp extracts formulated exclusively for dogs and cats

7 months ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

SAN DIEGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

7 months ago - GlobeNewsWire

PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and science PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and ...

8 months ago - GlobeNewsWire

CV™ Defense now available on CV Sciences website and launching on Amazon.com next week CV™ Defense now available on CV Sciences website and launching on Amazon.com next week

9 months ago - GlobeNewsWire

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is p...

9 months ago - GlobeNewsWire

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pl...

10 months ago - GlobeNewsWire

CV Sciences' (CVSI) CEO Joseph Dowling on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

THC-free Happy Lane™ expands CV Sciences’ sales channels and consumer access to safe and effective CBD THC-free Happy Lane™ expands CV Sciences’ sales channels and consumer access to safe and effective CBD

10 months ago - GlobeNewsWire

Clinically researched wide spectrum proprietary plant-based formula supports immune system and respiratory health Clinically researched wide spectrum proprietary plant-based formula supports immune syst...

10 months ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

10 months ago - Zacks Investment Research

SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) prod...

10 months ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CV Sciences Inc (CVSI) delivered earnings and revenue surprises of -66.67% and 37.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

CV Sciences, Inc. (CVSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -250.00% and -18.91%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

CV Sciences Is Worth Another Look

1 year ago - Seeking Alpha

Debra Borchardt, CEO, Co-founder and Editor-in-Chief of cannabis financial news site Green Market Report, joins us for our 50th episode to discuss the state of the cannabis market.

Other stocks mentioned: ACB, ACRGF, APHA, CGC, CRLBF, CWBHF, GTBIF ...
1 year ago - Seeking Alpha

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -300.00% and -32.29%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

However, one monstrous hurdle remains.

1 year ago - The Motley Fool

Shares of CV Sciences have tumbled recently due to broad concerns about the marijuana industry and greater competition.

1 year ago - Seeking Alpha

A move from the over-the-counter exchange to a major U.S. exchange may be coming for this trio of pot stocks.

Other stocks mentioned: CWBHF, MEDIF
1 year ago - The Motley Fool

Each and every one of these marijuana stocks has a lower forward P/E ratio than the S&P 500, but is growing substantially faster.

Other stocks mentioned: MEDIF, PLNHF, SPRWF, VGWCF
1 year ago - The Motley Fool

But do low volatility metrics translate to high confidence for these stocks' future prospects?

Other stocks mentioned: SMG, TRSSF
1 year ago - The Motley Fool

CV Sciences is profitable, sports a healthy gross margin, and generates positive free cash flow.

1 year ago - Seeking Alpha

CV Sciences has a much lower valuation than its closest rival, Charlotte's Web.

Other stocks mentioned: CWBHF
1 year ago - Seeking Alpha

Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.

Other stocks mentioned: CURLF, GWPH
1 year ago - The Motley Fool

Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?

Other stocks mentioned: CWBHF
1 year ago - The Motley Fool

These cannabis stocks all offer at least 36% upside.

Other stocks mentioned: CRLBF, CRON
1 year ago - The Motley Fool

Piper Jaffray likes several U.S. cannabis stocks and one Canadian pot stock better than Aurora.

Other stocks mentioned: CRLBF, CRON, CWBHF, GTBIF
1 year ago - The Motley Fool

Here's how companies from three different corners of the industry squeezed out a profit in the second quarter.

Other stocks mentioned: IIPR, KR
1 year ago - The Motley Fool

CBD product sales continued to soar in the second quarter, but not as much as analysts expected.

1 year ago - The Motley Fool

CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and -3.44%, respectively, for the quarter ended June 2019.

1 year ago - Zacks Investment Research

About CVSI

CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and con... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Stock Exchange
OTCMKTS
Ticker Symbol
CVSI
Full Company Profile

Analyst Forecasts

The average 12-month stock price forecast for CV Sciences is 0.60, which is an increase of 39.53% from the latest price.

Price Target
$0.60
(39.53% upside)